title: Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
abstract: We have previously shown that human renal cell carcinoma (RCC) cells express large numbers of interleukin-13 receptors (IL-13R), a newly described hemopoietic growth factor receptor. To target tumor cells that express IL-13R, we have produced a chimeric protein composed of human IL-13 and a derivative of Pseudomonas exotoxin A, termed PE38QQR. We report here that IL13-PE38QQR is highly cytotoxic to many human RCC cell lines. IL-13R-negative cell lines or cell lines expressing low numbers of IL-13R ( < 300 sites/cell) that include human bone marrow-derived cells were not susceptible to the cytotoxic effect of IL 13-PE38QQR. The sensitivity of RCC cells to IL13-PE38QQR correlated positively with the density of IL-13R. The cytotoxic activity of IL13-PE38QQR was competed by an excess of IL-13 in a protein synthesis inhibition assay and confirmed by a clonogenic assay. Even though IL-13 and IL-4 are homologues and IL-4R and IL-13R have been proposed to share a receptor subunit, IL-4 did not compete for the cytotoxicity mediated by IL13-toxin on RCC. IL13-PE38QQR competes for [125I]-IL-13 binding sites on RCC cells, although at a lower affinity than the wild-type recombinant cytokine. Human T-cell, B-cell, and monocytic cell lines are unresponsive to the cytotoxic action of IL13-PE38QQR. Thus, our results indicate that IL13-PE38QQR is highly cytotoxic to human RCC cells, although it is not cytotoxic to a variety of normal hematopoietic cells. IL13-PE38QQR should be further investigated preclinically for the treatment of human RCCs.
authors.affiliation: Laboratory of Molecular Tumor Biology, Food and Drug Administration, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Puri
authors.forename: P
authors.initials: P
authors.lastname: Leland
authors.forename: N I
authors.initials: NI
authors.lastname: Obiri
authors.forename: S R
authors.initials: SR
authors.lastname: Husain
authors.forename: R J
authors.initials: RJ
authors.lastname: Kreitman
authors.forename: G P
authors.initials: GP
authors.lastname: Haas
authors.forename: I
authors.initials: I
authors.lastname: Pastan
authors.forename: W
authors.initials: W
authors.lastname: Debinski
mesh_terms: D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D005098:Exotoxins / Q000235:genetics / Q000494:pharmacology*; D006801:Humans; D018793:Interleukin-13 / Q000235:genetics / Q000494:pharmacology*; D053661:Interleukin-13 Receptor alpha1 Subunit; D015847:Interleukin-4 / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000473:pathology*; D009363:Neoplasm Proteins / Q000187:drug effects*; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics / Q000494:pharmacology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D018123:Receptors, Interleukin / Q000187:drug effects*; D053660:Receptors, Interleukin-13; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D005098:Exotoxins; D018793:Interleukin-13; D053661:Interleukin-13 Receptor alpha1 Subunit; D015847:Interleukin-4; D009363:Neoplasm Proteins; D011065:Poly(ADP-ribose) Polymerases; D011500:Protein Synthesis Inhibitors; D018123:Receptors, Interleukin; D053660:Receptors, Interleukin-13; D011993:Recombinant Fusion Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C508181:IL13RA1 protein, human